Close
FINDING CURES TOGETHER<sup>SM</sup>

Tumor Immunology and Immunotherapy

Sunday, Nov. 17   

Monday, Nov. 18

Tuesday, Nov. 19

Wednesday, Nov. 20


Sunday, Nov. 17

Welcome and Keynote Lectures
5-7 p.m.

Updates in cell therapies
Crystal L. Mackall, Stanford University, Stanford, California

Story over time, discovery to translation, CTLA-4 and PD-1
Gordon J. Freeman, Dana-Farber Cancer Institute, Boston, Massachusetts


Opening Reception
7-9 p.m.


Monday, Nov. 18 

Continental Breakfast
7-8 a.m.

Plenary Session 1: Intersection of Signaling Pathways and Immuno-Oncology  
8-10 a.m.

STK11/LKB1 and other genomic drivers of a “cold” immune phenotype in NSCLC: Implications for precision immunotherapy
John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas

Impact on tumor-resident DC on anti-tumor immunity
Stefani Spranger, MIT Koch Institute for Integrated Cancer Research, Cambridge, Massachusetts

Title to be announced
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, Massachusetts


Break
10-10:30 a.m.


Plenary Session 2: Novel Cell Therapies  
10:30 a.m.-12:30 p.m.

Title to be announced
Aude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, Washington

Engineering natural killer cells for the treatment of cancer
Katayoun Rezvani, The University of Texas MD Anderson Cancer Center, Houston, Texas

Understanding resistance to develop next-generation CART for lymphoid malignancies
Marco Ruella, University of Pennsylvania, Philadelphia, Pennsylvania


Poster Session A / Lunch
12:30-3 p.m.


Plenary Session 3: Adverse Events  
3-5 p.m.

Study the relationship of tumor and autoimmunity in autoimmune-prone mice and humans
Jeffrey A. Bluestone, Parker Institute for Cancer Immunotherapy, San Francisco, California

Cardiovascular toxicities of cancer immunotherapies: From bench to bedside
Javid J. Moslehi, Vanderbilt University School of Medicine, Nashville, Tennessee 

Title to be announced
Antony Rosen, Johns Hopkins University, Baltimore, Maryland


Evening on Own
5 p.m.


Tuesday, Nov. 19

Continental Breakfast
7-8 a.m.


Plenary Session 4: Epigenomics of Immuno-Oncology  
8-10 a.m.

Title to be announced
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, Maryland

Reprogramming the epigenome for enhancing CAR T cell anti-tumor Efficacy
Joseph A. Fraietta, University of Pennsylvania, Philadelphia, Pennsylvania

Title to be announced
Andrea Schietinger, Memorial Sloan Kettering Institute, New York, New York


Break

10-10:30 a.m.


Plenary Session 5: Imaging and New Technologies  
10:30 a.m.-12:30 p.m.

Nanobodies as building blocks for the construction of immuno-oncology tools
Hidde Ploegh, Boston Children’s Hospital, Boston, Massachusetts

Whole body PD-L1 and PD-1 PET: First in human experience
David Leung, Bristol-Myers Squibb, Princeton, New Jersey

Title to be announced
Andrew H. Beck, PathAI, Boston, Massachusetts


Lunch on Own
12:30-2:30 p.m.


Plenary Session 6: Tumor Evolution, Tumor Heterogeneity, and Tumor Microenvironment
2:30 p.m.-4:30 p.m.

The impact of tumor microenvironment of clonal evolution in cancer
Samra Turajlic, The Francis Crick Institute, London, United Kingdom

Title to be announced
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

Chromatin state and scRNA-seq analysis defines a common differentiation trajectory towards T cell exhaustion
Christina Leslie, Memorial Sloan Kettering Cancer Center, New York, New York 


Poster Session B / Reception
4:30-7 p.m.

Wednesday, Nov. 20

Continental Breakfast
7-8 a.m.

Plenary Session 7: Interaction Between the Microbiome and Immunity, Systemic and Local Responses  
8-10 a.m.

The microbiota and colorectal cancer
Wendy Garrett, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

Title to be announced
Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France

The role of the gut microbiome in response and toxicity to cancer therapy
Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas


Break
10-10:30 a.m.


Plenary Session 8: Interface of Genetics, Antigens, and Immuno-Oncology, Including Vaccines, Adjuvants, and Biomarkers  
10:30 a.m.-12:30 p.m.

Driving T cells into tumors: a role for personal cancer vaccines
Catherine Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

Cell tansfer therapy for common epithelial cancers
Steven Rosenberg, National Cancer Institute, Bethesda, Maryland

Tumor intrinsic drivers of response and resistance to checkpoint blockade in MRD tumors
Luis Diaz, Memorial Sloan Kettering Cancer Center, New York, New York 

Closing Remarks
12:30 p.m.

Top of page